TRicuspid Uk STudy

Inclusion Criteria: * Patients aged \>18 years at recruitment * Severe or more symptomatic TR determined by transthoracic echocardiography * Optimized medical and/or device therapy for a minimum of 30 days * Medications, including diuretics should be stable over the past 30 days * Baseline KCCQ 75 or less on minimum 2 assessments at least 2 weeks apart * New York Heart Association (NYHA) Functional Class II or ambulatory class IV * Morphology of tricuspid valve suitable for TEER with expectation of a reduction of severity of TR to moderate or less * Willing to provide written informed consent Exclusion Criteria: * Presence of anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results or result in an expected life expectancy of less than 12 months * Active malignancy associated with a prognosis of \<1 year * Left ventricular ejection fraction (LVEF)\<20% * Tricuspid valve leaflet anatomy which may preclude TriClip implantation, proper clip positioning on the leaflets or sufficient reduction in TR. This may include: * Evidence of calcification in the grasping area * Presence of a severe coaptation defect (\>10mm) of the tricuspid leaflets. - Severe leaflet defect(s) preventing proper device placement * Ebstein Ano…